Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms

被引:23
作者
Aronovich, R
Gurwitz, D
Kloog, Y
Chapman, J [1 ]
机构
[1] Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel
[3] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Dept Neurol, IL-69978 Ramat Aviv, Israel
关键词
antiphospholipid syndrome; brain; endothelial cells; ERK; thrombin;
D O I
10.1016/j.imbio.2005.10.010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The antiphospholipid syndrome (APS) commonly affects the central nervous system through mechanisms that may include small vessel pathology and activation of thrombin. Antiphospholipid antibodies (aPL) activate endothelial cells but the specific activation of brain vascular endothelial cells (BVEC) and the receptors and signaling pathways involved have not been fully characterized. Objective: To examine whether aPL, the inflammatory stimulant lipopolysacharide (LPS) and thrombin activate BVECs through a Ras-dependent pathway. Methods: Rat BVEC (G8) were grown to confluence on 24-well plates. IgG was purified from 8 APS patients on a protein G column. Phosphorylation of ERK in the BVEC was measured by immunoblot utilizing a specific antibody. Results: Significant phosphorylation of ERK was measured following exposure of the cells to LPS and thrombin and this was blocked by the Ras inhibitor farnesylthiosalicylate (FTS). aPL IgG (1: 100 relative to serum) from 7/8 patients also induced phosphorylation of ERK. Conclusions: Activation of the Ras-ERK pathway is an effect of both APS IgG and thrombin. This pathway is potentially amenable to drugs such as FTS and may serve as a therapeutic target in APS. (C) 2005 Elsevier GmbH. All rights reserved.
引用
收藏
页码:781 / 788
页数:8
相关论文
共 68 条
[1]   ANTICARDIOLIPIN ANTIBODY AND STROKE - POSSIBLE RELATION OF VALVULAR HEART-DISEASE AND EMBOLIC EVENTS [J].
BARBUT, D ;
BORER, JS ;
WALLERSON, D ;
AMEISEN, O ;
LOCKSHIN, M .
CARDIOLOGY, 1991, 79 (02) :99-109
[2]   Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides [J].
Blank, M ;
Shoenfeld, Y ;
Cabilly, S ;
Heldman, Y ;
Fridkin, M ;
Katchalski-Katzir, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (09) :5164-5168
[3]  
Bordron A, 1998, ARTHRITIS RHEUM-US, V41, P1738, DOI 10.1002/1529-0131(199810)41:10<1738::AID-ART6>3.3.CO
[4]  
2-Z
[5]   INDUCTION OF ENDOTHELIAL-CELL TISSUE FACTOR ACTIVITY BY SERA FROM PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME - A POSSIBLE MECHANISM OF THROMBOSIS [J].
BRANCH, DW ;
RODGERS, GM .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 168 (01) :206-210
[6]   Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002 [J].
Brey, RL ;
Chapman, J ;
Levine, SR ;
Ruiz-Irastorza, G ;
Derksen, RHWM ;
Khamashta, M ;
Shoenfeld, Y .
LUPUS, 2003, 12 (07) :508-513
[7]  
Caronti B, 1999, CLIN EXP IMMUNOL, V115, P214
[8]   Anti-β2-glycoprotein I antibodies bind to central nervous system [J].
Caronti, B ;
Pittoni, V ;
Palladini, G ;
Valesini, G .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1998, 156 (02) :211-219
[9]   Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies [J].
Chapman, J ;
Rand, JH ;
Brey, RL ;
Levine, SR ;
Blatt, I ;
Khamashta, MA ;
Shoenfeld, Y .
LUPUS, 2003, 12 (07) :514-517
[10]   Antiphospholipid antibodies bind to activated but not resting endothelial cells: is an independent triggering event required to induce antiphospholipid antibody-mediated disease? [J].
Chen, Q ;
Stone, PR ;
Woon, ST ;
Ching, LM ;
Hung, S ;
McCowan, LME ;
Chamley, LW .
THROMBOSIS RESEARCH, 2004, 114 (02) :101-111